Trial of Ondansetron as a Parkinson's HAllucinations Treatment
Status:
Not yet recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
TOPHAT is a double blind, individually randomized, placebo-controlled, parallel group,
flexible dose trial of ondansetron (8-24mg/day) as a treatment for Parkinson's
hallucinations, with a 12-week primary outcome and follow-up to 24 weeks.